Table 3.
WHO group | Median survival by EGFR IHC (years) |
Overall P |
P values between EGFR IHC subgroups |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Neg | Weak | Mod | Strong | Neg vs weak | Neg vs mod | Neg vs strong | Weak vs mod | Weak vs strong | Mod vs strong | ||
All gliomas | Undefined | 1.6 | 1.9 | 0.99 | <0.0001⁎ | 0.029 | 0.058 | 0.0003⁎ | 0.50 | 0.0032⁎ | <0.0001⁎ |
Astrocytoma | |||||||||||
Grade II | Undefined | Undefined | 6.37 | Undefined | 0.32 | 0.25 | 0.21 | 0.14 | 0.45 | 0.25 | 0.40 |
Grade III | Undefined | 1.9 | 2.5 | 1.7 | 0.54 | 0.33 | 0.41 | 0.33 | 0.36 | 0.88 | 0.29 |
GBM | 1.2 | 0.68 | 0.57 | 0.80 | 0.097 | 0.23 | 0.12 | 0.39 | 0.43 | 0.36 | 0.025⁎ |
Oligodendroglioma | |||||||||||
Grade II | Undefined | Undefined | Undefined | 4.3 | 0.02⁎ | 0.37 | 0.40 | 0.050⁎ | 0.71 | 0.084 | 0.013⁎ |
Grade III | NA | 1.1 | Undefined | 2.7 | 0.03⁎ | NA | NA | NA | 0.025⁎ | 0.016⁎ | 0.79 |
A total of 750 diffusely infiltrative astrocytomas and oligodendrogliomas, WHO grades II to IV, were prospectively analyzed for EGFR expression via IHC semiquantification (see Materials and Methods). Median survival after diagnosis was determined by Kaplan-Meier curves, with statistical significance calculated via log-rank tests.
mod, moderate; NA, not available (no grade III oligodendrogliomas were immunonegative for EGFR); neg, negative.
Significant correlations.